The strong efficacy and clean safety profile de-risk SPY002 as a potential best-in-class anti-TL1A. Watch for Part B randomized placebo-controlled data and SPY003 readout in Q3 2026, which could further validate the platform. The stock may re-rate upward on this catalyst, but given the open-label design and small sample (n=48), some skepticism may persist until confirmatory data.
SYRE drugs
SYRE drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 15 $83.58entry
- T+1 · 5mo ago −0.20%α +0.39% · $83.41
- T+5 · 5mo ago +20.03%α +21.41% · $100.32
- T+20 · 4mo ago +12.14%α +12.89% · $93.73
- T+60 · 2mo ago +4.01%α +3.01% · $86.93
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Spyre Therapeutics announced positive 12-week induction topline data from Part A of the Phase 2 SKYLINE trial of SPY002 (anti-TL1A) in moderate-to-severe ulcerative colitis. The primary endpoint was met with a statistically significant 10.7-point reduction in Robarts Histopathology Index (RHI) score (p<0.0001), with clinical remission of 33% and endoscopic improvement of 42%. Safety was consistent with the TL1A class with no drug-related serious adverse events. This de-risks SPY002 and supports the ongoing Part B randomized portion and combination arms.
Key Facts
- Primary endpoint met: 10.7-point reduction in RHI from baseline at Week 12 (p<0.0001)
- Clinical remission rate of 33% and endoscopic improvement rate of 42%
- Change in modified Mayo Score of -3.7
- Safety profile consistent with TL1A class; 2 SAEs deemed not drug-related, no drug-related SAEs, no deaths
- Study population: 35% advanced therapy-exposed, mean disease duration 7.0 years, 56% baseline endoscopy score of 3
- Company on track for SPY003 (anti-IL-23) Part A data in Q3 2026 and Part B enrollment underway
Financial Impact
No financial data in filing; positive clinical data likely increases probability of technical and regulatory success for SPY002, potentially enhancing partnership or valuation prospects for a $7B market cap biotech
Risk Factors
- Open-label Part A design with no placebo control limits comparative interpretation
- Small sample size (n=48) may not fully capture safety signals
- Competitive landscape includes other anti-TL1A programs (e.g., duvakitug from Teva/Sanofi) with Phase 2b data
- Part B randomized data expected later; failure to replicate would reverse gains
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001636282-26-000083 |
| Exhibit: exhibit99120260615skyline-.htm | 0001636282-26-000083 |
| Document: 0001636282-26-000083-index-headers.html | 0001636282-26-000083 |
| Document: 0001636282-26-000083-index.html | 0001636282-26-000083 |
| Document: 0001636282-26-000083.txt | 0001636282-26-000083 |
Track record
36 reports on SYRE
7 of 11 bullish or bearish reports moved the stock their way by T+60. Best: +54.27% at T+60 after the Apr 13, 2026 report. 14 of 20 went positive at some point.
Filters
- Nov 3, 202613d ago 8-K Neutral 5/10 No price data
- Nov 3, 202613d ago Press Release Bearish 5/10 Entry $99.04 Now $99.37 −0.33% settles Feb 2
- Oct 12, 20265w ago Institutional Cluster Bullish 4/10 Entry $85.90 Now $99.37 +15.68% settles Jan 7
- Oct 9, 20265w ago SC 13D/A Neutral 3/10 Entry $85.90 Now $99.37 +15.68% settles Jan 7
- Oct 7, 20265w ago 8-K Bearish 5/10 Entry $80.85 Now $99.37 −22.91% settles Jan 4
- Oct 6, 20265w ago 424B5 Bearish 6/10 Entry $80.85 Now $99.37 −22.91% settles Jan 4
- Oct 5, 20266w ago Press Release Bearish 6/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
- Oct 5, 20266w ago 424B5 Bearish 5/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
- Oct 5, 20266w ago Press Release Bearish 5/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
- Oct 2, 20266w ago Insider Cluster Bearish 4/10 Entry $92.72 Now $99.37 −7.17% settles Dec 30
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers